Guard therapeutics

See the webcast. Guard Therapeutics is a Swedish biotech company that identifies and develops new therapies for diseases with a great medical need for more effective treatments, guard therapeutics. Learn more guard therapeutics the clinical development of RMC

The Company conducts development and commercialization of treatment and diagnostics based on the alphamicroglobulin A1M protein. The protein serves as a radical inhibitor, an antioxidant, a protector against free hemoglobin and a tissue repairer. A1M is a candidate for different therapeutic and diagnostic u ses, such as alleviation of autoimmune diseases and stroke treatment. The Company develops a drug for intravenous treatment of preeclampsia, a condition that can occur during pregnancy and can contribute to premature deliveries. Financial Times Close.

Guard therapeutics

The presentation included an update on next development steps for the drug candidate RMC and progress within the preclinical development platform of new peptides intended for chronic treatment. A recording of the presentation is available on the company's website. The program began with the company's CEO, Tobias Agervald, providing a summary of the strategic considerations and positive feedback from the FDA that form the basis for the next development stages of RMC, including a planned Phase 2b study in open-heart surgery. Furthermore, the discussion also covered the way forward and the strategy for an upcoming pivotal Phase 3 study. Professor David Goldsmith, adjunct professor at King's College in London and a globally recognized Key Opinion Leader in nephrology, delivered a comprehensive presentation on irreversible loss of kidney function following open-heart surgery, highlighting the lack of specific treatment options despite the significant medical need. Professor Goldsmith also discussed the main findings of the AKITA study, which included positive and clinically relevant long-term effects on kidney function after treatment with RMC The company's Chief Medical Officer, Dr. CEO Tobias Agervald then presented new advancements in the company's preclinical development platform, the so-called GTX platform, aimed at developing new peptides short protein fragments based on the endogenous protein alphamicroglobulin. The overall goal is to identify new drug candidates tailored for the treatment of chronic diseases. The peptide GTX, along with other similar peptides, has demonstrated robust therapeutic effects in several experimental models representing various forms of kidney disease, including kidney injuries caused by oxygen deprivation known as ischemia-reperfusion injury and by the chemotherapy agent cisplatin. Additional concept validation studies have also been conducted with up to 28 days of treatment in two models of chronic kidney disease, including diabetes-induced kidney disease and focal segmental glomerulosclerosis FSGS.

Cancel Continue.

.

Guard Therapeutics is a Swedish biotechnology company that develops novel therapies for diseases with a great medical need for more effective treatments. Our key therapeutic area is nephrology with a focus on acute kidney injuries. Our company is driven by a small team of world-leading scientific, medical and drug development expertise within nephrology. RMC is our most advanced investigational drug which is being developed as a kidney protective treatment in patients undergoing open heart surgery. It is currently in Phase 2 clinical development with a global Phase 2 study running both in Europe and North America. This is also an important seal of quality given the rigorous assessment conducted by the FDA within the framework of an IND application. Guard Therapeutics has also been granted Fast Track designation by the FDA for reducing the risk of an irreversible loss of kidney function, initiation of kidney replacement therapy or death following open-chest cardiac surgery in patients who are at increased risk for acute kidney injury. Consequently, treatment with RMC has the potential to save lives and prevent other severe consequences of acute kidney injury such loss of kidney function and need for renal replacement therapy.

Guard therapeutics

The presentation included an update on next development steps for the drug candidate RMC and progress within the preclinical development platform of new peptides intended for chronic treatment. A recording of the presentation is available on the company's website. New preclinical results from the company's peptide platform will also be presented. The next developmental step includes a phase 2b study with the aim of identifying an optimal dosage of RMC The phase 2b study is also expected to enable the most efficient design of a subsequent pivotal phase 3 study. Guard Therapeutics [GUARD], a biotechnology company specializing in kidney diseases, today announced further information regarding the development strategy for the investigational drug RMC An advisory meeting with the U. Food and Drug Administration FDA will be requested to explore dose optimization and the framework for a future registrational trial for the prevention of kidney injury in open-heart surgery. The development strategy is based on the recent top-line results of the Phase 2 AKITA study, which demonstrated statistically significant and clinically relevant long-term kidney-protective effects of RMC after open-heart surgery. The study aims to evaluate the kidney protective effect of the investigational drug RMC in relation to open heart surgery.

Hot chicks pooping

The company has thus achieved an important milestone by expanding the clinical development program to a second indication where RMC has the potential to protect against acute kidney injuries. Professor Goldsmith also discussed the main findings of the AKITA study, which included positive and clinically relevant long-term effects on kidney function after treatment with RMC A1M is a candidate for different therapeutic and diagnostic u ses, such as alleviation of autoimmune diseases and stroke treatment. Arribatec Group ASA. The overall goal is to identify new drug candidates tailored for the treatment of chronic diseases. Learn more about the clinical development of RMC Press releases. Partnera Oyj. For further information, please contact:. Financial calender Financial reports Share information Corporate governance General meetings.

See the webcast. Guard Therapeutics is a Swedish biotech company that identifies and develops new therapies for diseases with a great medical need for more effective treatments. Learn more about the clinical development of RMC

Wise Group AB. Show more US link US. Add to Your Watchlists New watchlist. Professor David Goldsmith, adjunct professor at King's College in London and a globally recognized Key Opinion Leader in nephrology, delivered a comprehensive presentation on irreversible loss of kidney function following open-heart surgery, highlighting the lack of specific treatment options despite the significant medical need. Fable Media Group AB. A1M is a candidate for different therapeutic and diagnostic u ses, such as alleviation of autoimmune diseases and stroke treatment. The company's Chief Medical Officer, Dr. Read more. Partnera Oyj. Guard Therapeutics Intrntnl AB publ. Additional concept validation studies have also been conducted with up to 28 days of treatment in two models of chronic kidney disease, including diabetes-induced kidney disease and focal segmental glomerulosclerosis FSGS. Speqta AB publ.